Swedish Real Estate Stock News

Thinking about whether Essity is a bargain or overpriced? Let's investigate what its current share price means for potential investors like you. Essity's stock has seen a slight dip of 0.3% over the past week, yet it surged 5.4% in the last month, even as the longer-term performance remains mixed. Recent headlines spotlight Essity's strategic moves in sustainability and product innovation, fueling conversations about its growth prospects and how these efforts might offset broader market...

Mycronic (OM:MYCR) just released its third quarter numbers, revealing a drop in both quarterly sales and net income compared to last year. At the same time, it maintained its full-year sales guidance, reflecting steady confidence going forward. See our latest analysis for Mycronic. Despite the recent dip in quarterly earnings, Mycronic’s confidence in its full-year outlook has helped sustain positive momentum. The shares have delivered a 6.8% gain so far this year. Looking further out,...

AcadeMedia (OM:ACAD) reported a net profit margin of 4.3%, up from 3.7% last year, with EPS growth over the past year reaching 26.6%. The company’s average annual earnings growth of 6.2% over the past five years, along with a forecasted 13.9% annual growth rate, puts it ahead of the broader Swedish market’s expected 12.8%. As investors consider AcadeMedia’s improving profitability and future outlook, sentiment may become more favorable in the quarters ahead. See our full analysis for...

Camurus (OM:CAMX) has launched Oczyesa, a long-acting octreotide medication for adults with acromegaly. The drug is now first available in Germany after receiving marketing authorization from the European Commission. The drug can be self-administered using an autoinjector pen, a feature designed to improve both convenience and overall quality of life for patients managing this rare condition. See our latest analysis for Camurus. On the back of the Oczyesa launch, Camurus has seen its momentum...

As the European markets face mixed performances with major stock indexes showing varied results, the pan-European STOXX Europe 600 Index recently dipped slightly after reaching a new high. In this fluctuating environment, growth companies with high insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.

As the European market navigates a mixed landscape with major stock indexes showing varied performance, investors are keeping a close eye on opportunities that may arise from current economic conditions. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing prospects despite their somewhat outdated moniker. These stocks can provide an affordable entry point into the market and potential growth when backed by strong financials. In this article, we explore...

Potential Betsson AB (publ) ( STO:BETS B ) shareholders may wish to note that the Director, Peter Hamberg, recently...

The recent earnings posted by Catena AB (publ) ( STO:CATE ) were solid, but the stock didn't move as much as we...

Key Insights The projected fair value for Devyser Diagnostics is kr156 based on 2 Stage Free Cash Flow to Equity...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Nelly Group AB (publ)'s ( STO:NELLY ) stock was strong after they recently reported robust earnings. However, our...

The subdued market reaction suggests that Dedicare AB (publ)'s ( STO:DEDI ) recent earnings didn't contain any...

Eastnine AB (publ) ( STO:EAST ) recently released a strong earnings report, and the market responded by raising the...

Key Insights The projected fair value for Clas Ohlson is kr292 based on 2 Stage Free Cash Flow to Equity Current share...

Key Insights Enad Global 7's significant insider ownership suggests inherent interests in company's expansion A total...

Viaplay Group AB (publ) ( STO:VPLAY B ) shareholders won't be pleased to see that the share price has had a very rough...

Pandox (OM:PNDX B) shares have drawn fresh attention after the company posted a clear jump in net income for the third quarter, shifting from a net loss last year to a solid profit. Alongside the earnings lift, management revealed plans to accelerate acquisitions and indicated that current market conditions could support both buying and selling assets. See our latest analysis for Pandox. Pandox’s latest acquisition push and jump in profits come as its share price has steadily climbed, with a...

BioGaia (OM:BIOG B) just shared breakthrough research showing that two gut bacterial strains can generate serotonin, a neurotransmitter mostly made in the intestine. This discovery opens up new avenues for gut-brain health. See our latest analysis for BioGaia. While BioGaia’s serotonin breakthrough has put a spotlight back on its innovation, the stock tells a more nuanced story. After some short-term volatility and a recent earnings beat, the 1-year total shareholder return is nearly flat at...

Invisio AB (publ) recently announced its third-quarter 2025 results, reporting sales of SEK291.3 million and a net loss of SEK4.2 million, compared to sales of SEK351.7 million and net income of SEK38.9 million a year earlier. This marks a shift from profitability to a loss, underscoring a year-over-year deterioration in both sales and earnings performance. Given Invisio's move to a quarterly loss after several years of profitability, we'll evaluate how this development impacts the company's...

Sectra (OM:SECT B) recently shared that Region Stockholm will roll out its enterprise imaging cloud service across all hospitals in Stockholm and Gotland. This step unifies imaging systems and aims for greater security and streamlined healthcare operations. See our latest analysis for Sectra. Sectra’s announcement comes after a year marked by solid long-term gains and some recent volatility. While the share price is up 5.99% year-to-date, a dip of 4.53% over the last week and a 15.29% fall in...

Implantica (OM:IMP A SDB) saw momentum build this week after the company received positive feedback from the FDA on its RefluxStop device. Recent inspections wrapped up smoothly and set the stage for potential U.S. market entry. See our latest analysis for Implantica. That FDA feedback has energized investors, but it comes after an intense year of ups and downs for Implantica. Despite a sharp short-term pullback, such as a 25.9% one-month share price return, the stock's 43.7% year-to-date...

Getinge (OM:GETI B) reaffirmed its guidance for 2025, confirming expectations for 2% to 5% organic net sales growth and targeting over 12% earnings per share growth, even with ongoing headwinds from tariffs and currency shifts. See our latest analysis for Getinge. Backed by steady guidance and resilience in the face of tariffs and currency changes, Getinge’s shares have climbed with conviction this year, posting a robust 21.6% year-to-date share price return and an impressive 1-year total...

Nyfosa (OM:NYF) has just released its third quarter and nine-month results for 2025, highlighting a return to profitability after a period of losses. This turnaround in earnings is drawing attention from investors who are watching the company’s recovery. See our latest analysis for Nyfosa. Nyfosa’s return to profitability comes at a time when its share price remains under pressure, with a year-to-date decline of 24.27%. While the recent earnings turnaround and moves like the planned...

Attendo (OM:ATT) has drawn renewed attention after its latest earnings update. While sales and revenue slipped slightly compared to last year, both net income and earnings per share saw significant gains for the quarter and the year to date period. See our latest analysis for Attendo. Attendo’s recent buyback and improving profitability have clearly caught investors’ attention, contributing to the stock’s sharp momentum. The 1-month share price return stands at 17.8%, and total shareholder...